Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
150 stopped studies mapped to Hodgkin Lymphoma and descendants · 86% state a reason
Over the 150 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01947140 | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies(PDX+Romi) | Phase 1 / Phase 2 | terminated | Sep 20, 2013 | Jennifer Amengual | Lack of funding and recruitment complications caused by COVID-19 | COVID-19 / pandemic |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | Phase 2 | suspended | Nov 8, 2024 | Leland Metheny | insufficient funding | Funding |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and… | Phase 1 / Phase 2 | terminated | Jul 26, 2018 | Merck Sharp & Dohme LLC | Business Reason | Sponsor / business decision |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT06120504 | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers | Phase 1 | terminated | Nov 7, 2023 | Seagen, a wholly owned subsidiary of Pfizer | Study terminated as part of strategic considerations | Sponsor / business decision |
| NCT06254495 | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers | Phase 1 | terminated | Feb 12, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons due to portfolio reprioritization. The decision was… | Safety / toxicity |
| NCT04788043 | Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma | Phase 2 | terminated | Mar 9, 2021 | Ranjana Advani | Discontinuation of magrolimab development | Other (stated, no rule matched) |
| NCT05255601 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of…(RELATIVITY-069) | Phase 1 / Phase 2 | terminated | Feb 24, 2022 | Bristol-Myers Squibb | not stated | Not stated |
| NCT04758650 | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis,…(MITRAS) | Phase 2 | terminated | Feb 17, 2021 | Universitair Ziekenhuis Brussel | Delay in recruitment | Enrollment / accrual |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced… | Phase 1 | terminated | Mar 11, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare… | Phase 2 | suspended | Apr 20, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | Phase 1 | terminated | Nov 4, 2022 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT04486391 | Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical… | Phase 3 | terminated | Jul 24, 2020 | BeiGene | Study has voluntarily discontinued due to a change in the company-level development strategy and is… | Safety / toxicity |
| NCT05938127 | Impact of Respiratory Training in Lymphoma Survivors | N/A | terminated | Jul 10, 2023 | University of Colorado, Denver | Low Accrual | Enrollment / accrual |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory… | Phase 1 | terminated | Apr 6, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05179603 | A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of… | Phase 2 | terminated | Jan 5, 2022 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT06018129 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | terminated | Aug 30, 2023 | Genmab | Genmab discontinued GEN3017 program following a strategic re-evaluation of Genmab's portfolio. | Sponsor / business decision |
| NCT03646123 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | Phase 2 | terminated | Aug 24, 2018 | Seagen Inc. | The study was prematurely discontinued as the sponsor believes the data collected is enough to show… | Safety / toxicity |
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+…(NAVAL-1) | Phase 2 | terminated | Aug 18, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | Phase 1 / Phase 2 | terminated | May 9, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Poor accrual | Enrollment / accrual |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With… | Phase 1 | terminated | Feb 14, 2018 | Mayo Clinic | funding - sponsor filing Chapter 11 bankruptcy | Funding |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched… | Phase 2 | terminated | Feb 14, 2012 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA… | Phase 2 | terminated | Aug 3, 2018 | Memorial Sloan Kettering Cancer Center | Low accrual | Enrollment / accrual |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05181540 | A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous…(E-CELERATE) | Phase 3 | terminated | Jan 6, 2022 | Angiocrine Bioscience | Interim analysis showed lack of efficacy | Efficacy / futility |
| NCT03417765 | Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas | Phase 1 / Phase 2 | withdrawn | Jan 31, 2018 | GlyPharma Therapeutics | Business decision | Sponsor / business decision |
| NCT05134740 | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).(pediTACTAL) | Phase 1 | withdrawn | Nov 26, 2021 | Baylor College of Medicine | Leadership determination | Other (stated, no rule matched) |
| NCT01998035 | Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | Phase 1 / Phase 2 | terminated | Nov 28, 2013 | Columbia University | PI left institution | Investigator |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | Phase 1 | terminated | Jun 26, 2017 | Roncarolo, Maria Grazia, MD | Lack of Enrollment | Enrollment / accrual |
| NCT04072393 | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | N/A | terminated | Aug 28, 2019 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT00838955 | Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma | Phase 2 | terminated | Feb 9, 2009 | Loyola University | There was lack of enrollment since January 2013 | Enrollment / accrual |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | Phase 2 | terminated | Dec 8, 2015 | University of Virginia | Poor enrollment | Enrollment / accrual |
| NCT05711628 | A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab)… | Phase 3 | withdrawn | Feb 3, 2023 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT06104878 | A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With… | — | withdrawn | Oct 27, 2023 | Takeda | Company decision after projects re-evaluation, taken before the study initiation | Sponsor / business decision |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT03495713 | Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR… | Phase 2 | terminated | Apr 12, 2018 | Abramson Cancer Center at Penn Medicine | Covid-19 | COVID-19 / pandemic |
| NCT03138499 | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in…(CheckMate 812) | Phase 3 | terminated | May 3, 2017 | Bristol-Myers Squibb | Insufficient enrollment. | Enrollment / accrual |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT04621604 | Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients…(REVOLUMHOD) | N/A | terminated | Nov 9, 2020 | Rennes University Hospital | lack of eligible patients | Other (stated, no rule matched) |
| NCT03947255 | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma… | Phase 2 | terminated | May 13, 2019 | Seagen Inc. | Study stopped early due to low patient accrual. | Enrollment / accrual |
| NCT04952584 | Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in… | Phase 1 | withdrawn | Jul 7, 2021 | Baylor College of Medicine | Study was not activated | Other (stated, no rule matched) |
| NCT03776864 | Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical… | Phase 2 | terminated | Dec 17, 2018 | University of Washington | Company providing drug terminated their oncology program | Sponsor / business decision |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05169151 | Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors… | — | withdrawn | Dec 23, 2021 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT01316146 | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART… | Phase 1 | withdrawn | Mar 16, 2011 | UNC Lineberger Comprehensive Cancer Center | Study never truly opened to accrual at UNC. Study and data were transfered to UNC as the IND for… | Enrollment / accrual |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT01165645 | Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With… | N/A | withdrawn | Jul 20, 2010 | Mayo Clinic | no patients enrolled | Enrollment / accrual |
| NCT00496431 | phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma… | Phase 1 / Phase 2 | terminated | Jul 4, 2007 | Italfarmaco | Study accrual was stopped earlier than planned by the Sponsor for 2 main reasons: very slow… | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 13 days agoSource updated Sep 16, 2026source: clinicaltrials